EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies

Genia Kretzschmar, Laura Piñero Páez, Ziyang Tan, Jun Wang, Laura Gonzalez, Constantin Habimana Mugabo, Anette Johnsson, Yang Chen, Jaromír Mikeš, Tadepally Lakshmikanth, Anna James, Raphaela Goldbach-Mansky und 5 weitere

Journal of Clinical Immunology · 2025-12 · 45 (1)

DOI: 10.1007/s10875-024-01826-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 23.10.2024. Verfasst von Genia Kretzschmar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Clinical Pediatrics, Dept. of Women's and Children's Health, Karolinska Institutet, 17165, Solna, Sweden. Hauptthemen laut MEDLINE: Receptor, Interferon alpha-beta, Antibodies, Monoclonal, Humanized, Interferon Type I. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A causal role of type-I interferons (IFN-I) in autoinflammatory type-I interferonopathies such as SAVI (STING–associated vasculopathy with onset in infancy) and CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) is suggested by elevated expression of IFN-I stimulated genes (ISGs). Hitherto, the lack of specific inhibitors of IFN-I signaling has prevented the verification of a causal role for IFN-I in these conditions. Commonly used inhibitors of the JAK/STAT pathway exert broad effects on multiple signaling pathways leading to more general immunosuppression beyond IFN-I signaling.

Methods

Here we show in four patients with SAVI and one patient with CANDLE syndrome that blockade of the IFNAR1 receptor (Anifrolumab) exerts an additive effect over JAK-inhibitor alone. In two patients with SAVI, monotherapy with Anifrolumab is sufficient to retain a suppressed IFN-I signature and clinical improvement.

Results

Anifrolumab normalizes IFN-I signature genes and relieves symptoms beyond what is typically achieved by a JAK-inhibitor (Baricitinib) alone in patients with type-I interferonopathies. In two patients Anifrolumab was used successfully as monotherapy. Addition of Anifrolumab enabled steroid tapering and cessation with reduced overall immunosuppression and lower risks of opportunistic infections and improved metabolic states and growth which is highly beneficial in these young patients.

Conclusion

These results verify a causal role of IFN-I signaling in type-I Interferonopathies SAVI and CANDLE and suggests Anifrolumab as an important new treatment option in autoinflammatory diseases with elevated IFN-I induced gene expression. Genia Kretzschmar, Laura Piñero Páez, and Ziyang Tan are shared-first authors. Sara Alehashemi, AnnaCarin Horne, and Petter Brodin are co-senior author.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Interferon alpha-betaAntibodies, Monoclonal, HumanizedInterferon Type IHumansFemaleMaleSignal TransductionAntibodies, BlockingSulfonamidesTreatment OutcomePyrazolesJanus Kinase InhibitorsAzetidinesPurines

Stichwörter der Autor:innen

IFN-I, type I IFN, IFNAR1, Interferonopathies, Anifrolumab

Substanzen

Receptor, Interferon alpha-betaAntibodies, Monoclonal, HumanizedInterferon Type IanifrolumabIFNAR1 protein, humanbaricitinibAntibodies, BlockingSulfonamidesPyrazolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Unit for Clinical Pediatrics, Dept. of Women's and Children's Health, Karolinska Institutet, 17165, Solna, Sweden.
  • Unit for Pediatric Rheumatology, Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Solna, Sweden.
  • National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.
  • Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden.
  • Unit for Clinical Pediatrics, Dept. of Women's and Children's Health, Karolinska Institutet, 17165, Solna, Sweden. petter.brodin@ki.se.
  • Unit for Pediatric Rheumatology, Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Solna, Sweden. petter.brodin@ki.se.

Förderung

  • Karolinska Institute

Zitieren

APA

Kretzschmar, G., Páez, L. P., Tan, Z., Wang, J., Gonzalez, L., Mugabo, C. H., Johnsson, A., Chen, Y., Mikeš, J., Lakshmikanth, T., James, A., Goldbach-Mansky, R., Fischer, M., Palmblad, K., Alehashemi, S., Horne, A., & Brodin, P. (2025). Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-024-01826-2

Vancouver

Kretzschmar G, Páez LP, Tan Z, Wang J, Gonzalez L, Mugabo CH, et al. Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-024-01826-2

BibTeX
@article{Kretzschmar2025,
  author = {Kretzschmar, Genia and Páez, Laura Piñero and Tan, Ziyang and Wang, Jun and Gonzalez, Laura and Mugabo, Constantin Habimana and Johnsson, Anette and Chen, Yang and Mikeš, Jaromír and Lakshmikanth, Tadepally and James, Anna and Goldbach-Mansky, Raphaela and Fischer, Marie and Palmblad, Karin and Alehashemi, Sara and Horne, AnnaCarin and Brodin, Petter},
  title = {Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10875-024-01826-2}
}
Kostenlos starten →